Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease

RMD Open. 2023 Feb;9(1):e002832. doi: 10.1136/rmdopen-2022-002832.

Authors

Omar Al Tabaa^#¹, Roba Ghossan^#¹, Alice Combier¹, Alexia Steelandt¹, Marion Thomas¹, Jerome Avouac^#¹, Yannick Allanore^#²

Affiliations

¹ Department of Rheumatology, Cochin Hospital, APHP, Université Paris Cité, Paris, France.
² Department of Rheumatology, Cochin Hospital, APHP, Université Paris Cité, Paris, France yannick.allanore@aphp.fr.

^# Contributed equally.

No abstract available

Keywords: Immune System Diseases; Rituximab; Systemic Sclerosis.

Publication types

Letter

MeSH terms

Connective Tissue
Connective Tissue Diseases* / complications
Connective Tissue Diseases* / drug therapy
Humans
Lung Diseases, Interstitial* / drug therapy
Lung Diseases, Interstitial* / etiology
Rituximab / therapeutic use

Substances

Rituximab